|
| Monday, September 12, 2022 |
|
|
Eisai and Merck & Co., Inc. Present Results from Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma |
| Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada) today announced the first presentation of results from the final analysis of the Phase 3 LEAP-002 trial investigating LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA. more info >> |
|
|
Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022 |
| Eisai Co., Ltd. announced today results from a post hoc analysis of three randomized, pivotal, Phase 3 studies. more info >> |
|
| Tuesday, September 6, 2022 |
|
|
Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022 |
| Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2022, which is taking place virtually and in-person in Paris, France from September 9 to 13. more info >> |
|
| Wednesday, August 24, 2022 |
|
|
Eisai Inc. Collaborates with C2N to Build Awareness and Real-World Evidence for Blood-based Assays |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has entered into a memorandum of understanding with C2N Diagnostics ("C2N") that will seek to build awareness about how blood-based assays in the diagnosis for people living with cognitive impairment, including Alzheimer's disease (AD), may help patients receive a timely diagnosis and appropriate treatment. more info >> |
|
| Tuesday, August 9, 2022 |
|
|
Eisai and Lifenet Enter Into Capital and Business Alliance Agreement Aimed at Building Ecosystem to Reduce Burden of Medical and Nursing Care |
| Eisai Co., Ltd. and LIFENET INSURANCE COMPANY announced today that they have entered into a capital and business alliance agreement to collaborate in dementia and other areas, with the aim of helping reduce the burden of medical and nursing care for people living in Japan's aging society. more info >> |
|
| Thursday, August 4, 2022 |
|
|
Eisai Presents New Findings on Lecanemab's Investigational Subcutaneous Formulation and Modeling Simulation of ApoE4 Genotype on Aria-E Incidence at AAIC 2022 |
| Eisai Co., Ltd. and Biogen Inc. announced that Eisai presented new findings on a subcutaneous formulation of lecanemab (BAN2401) and the modeling simulation of the impact of ApoE4 genotype. more info >> |
|
|
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial |
| Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada) today announced that the Phase 3 LEAP-002 trial investigating LENVIMA. more info >> |
|
| Tuesday, July 26, 2022 |
|
|
Eisai Listed for 21st Consecutive Year in FTSE4Good Index Series |
| Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 21st consecutive year since its initial inclusion in 2002. more info >> |
|
|
Eisai to Present at The Alzheimer's Association International Conference (AAIC) 2022 |
| Eisai Co. Ltd announced today that the company will present research from its Alzheimer's disease (AD) pipeline, including new data for lecanemab (BAN2401). more info >> |
|
| Wednesday, July 6, 2022 |
|
|
U.S. FDA Accepts and Grants Priority Review for Eisai's Biologics License Application of Lecanemab |
| Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) under the accelerated approval pathway for lecanemab. more info >> |
|
|
|
